Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine

Maurizio Fava, Rosemarie Mulroy, Jonathan E. Alpert, Andrew A. Nierenberg, Jerrold F. Rosenbaum

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Objective: The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration. Method: The subjects were 20 outpatients with major depressive disorder who had participated in a multicenter, double-blind, placebo-controlled study of the efficacy of the new extended-release formulation of venlafaxine. Results: During the 3 days after discontinuation of treatment with the study drug, seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine placebo-treated patients reported the emergence of adverse events, a statistically significant difference. Conclusions: These results suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medication dose gradually.

Original languageEnglish (US)
Pages (from-to)1760-1762
Number of pages3
JournalAmerican Journal of Psychiatry
Volume154
Issue number12
StatePublished - 1997
Externally publishedYes

Fingerprint

Placebos
Major Depressive Disorder
Therapeutics
Outpatients
Venlafaxine Hydrochloride
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. / Fava, Maurizio; Mulroy, Rosemarie; Alpert, Jonathan E.; Nierenberg, Andrew A.; Rosenbaum, Jerrold F.

In: American Journal of Psychiatry, Vol. 154, No. 12, 1997, p. 1760-1762.

Research output: Contribution to journalArticle

Fava, M, Mulroy, R, Alpert, JE, Nierenberg, AA & Rosenbaum, JF 1997, 'Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine', American Journal of Psychiatry, vol. 154, no. 12, pp. 1760-1762.
Fava, Maurizio ; Mulroy, Rosemarie ; Alpert, Jonathan E. ; Nierenberg, Andrew A. ; Rosenbaum, Jerrold F. / Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. In: American Journal of Psychiatry. 1997 ; Vol. 154, No. 12. pp. 1760-1762.
@article{66fa0f950c654704b49ab054a0629db5,
title = "Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine",
abstract = "Objective: The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration. Method: The subjects were 20 outpatients with major depressive disorder who had participated in a multicenter, double-blind, placebo-controlled study of the efficacy of the new extended-release formulation of venlafaxine. Results: During the 3 days after discontinuation of treatment with the study drug, seven (78{\%}) of the nine venlafaxine-treated subjects and two (22{\%}) of the nine placebo-treated patients reported the emergence of adverse events, a statistically significant difference. Conclusions: These results suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medication dose gradually.",
author = "Maurizio Fava and Rosemarie Mulroy and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Rosenbaum, {Jerrold F.}",
year = "1997",
language = "English (US)",
volume = "154",
pages = "1760--1762",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "12",

}

TY - JOUR

T1 - Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine

AU - Fava, Maurizio

AU - Mulroy, Rosemarie

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Rosenbaum, Jerrold F.

PY - 1997

Y1 - 1997

N2 - Objective: The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration. Method: The subjects were 20 outpatients with major depressive disorder who had participated in a multicenter, double-blind, placebo-controlled study of the efficacy of the new extended-release formulation of venlafaxine. Results: During the 3 days after discontinuation of treatment with the study drug, seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine placebo-treated patients reported the emergence of adverse events, a statistically significant difference. Conclusions: These results suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medication dose gradually.

AB - Objective: The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration. Method: The subjects were 20 outpatients with major depressive disorder who had participated in a multicenter, double-blind, placebo-controlled study of the efficacy of the new extended-release formulation of venlafaxine. Results: During the 3 days after discontinuation of treatment with the study drug, seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine placebo-treated patients reported the emergence of adverse events, a statistically significant difference. Conclusions: These results suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medication dose gradually.

UR - http://www.scopus.com/inward/record.url?scp=0030712220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030712220&partnerID=8YFLogxK

M3 - Article

VL - 154

SP - 1760

EP - 1762

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 12

ER -